Related Experiment Video
Updated: Jul 9, 2026
07:50
Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Abstract:
Severe gram-positive infections: no advantage, but risk of muscle disorders.
Insights
For severe gram-positive infections, this study found no added benefits. However, there was an increased risk of developing muscle disorders with treatment.
Area of Science:
- Infectious Diseases
- Pharmacology
- Toxicology
Background:
- Gram-positive bacterial infections pose significant public health challenges.
- Current treatment guidelines aim for optimal efficacy and safety.
- Understanding potential adverse effects is crucial for patient management.
Purpose of the Study:
- To evaluate the efficacy of a specific treatment for severe gram-positive infections.
- To assess the risk of adverse events, particularly muscle disorders, associated with this treatment.
Main Methods:
- A retrospective analysis of patient data was conducted.
- Inclusion criteria focused on patients with severe gram-positive infections.
- Data on treatment outcomes and adverse events, including myopathy, were collected and analyzed.
Main Results:
- The treatment demonstrated no significant advantage in treating severe gram-positive infections compared to standard care.
- A notable association was found between the treatment and an increased incidence of muscle disorders.
- Specific types of muscle damage were identified in a subset of patients.
Conclusions:
- The studied treatment offers no clear benefit for severe gram-positive infections.
- Clinicians should be aware of the potential risk of myopathy and other muscle disorders.
- Careful patient monitoring is recommended when considering this treatment option.
Related Concept Videos
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:32Pinching-off of Coated Vesicles
Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...